740 related articles for article (PubMed ID: 15055140)
1. [Antimicrobial prophylaxis and therapy in neutropenia].
Link H
Mycoses; 2003; 46 Suppl 2():21-32. PubMed ID: 15055140
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial therapy of unexplained fever in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society).
Link H; Böhme A; Cornely OA; Höffken K; Kellner O; Kern WV; Mahlberg R; Maschmeyer G; Nowrousian MR; Ostermann H; Ruhnke M; Sezer O; Schiel X; Wilhelm M; Auner HW; ;
Ann Hematol; 2003 Oct; 82 Suppl 2():S105-17. PubMed ID: 13680173
[TBL] [Abstract][Full Text] [Related]
3. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
Tamura K
Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
[TBL] [Abstract][Full Text] [Related]
4. [Application of the concepts of evidence-based medicine to the evidence on the treatment of febrile neutropenia].
Jarque I; Sanz MA
Enferm Infecc Microbiol Clin; 1999; 17 Suppl 2():95-102. PubMed ID: 10605194
[TBL] [Abstract][Full Text] [Related]
5. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Why empirical therapy?
Klastersky J
J Antimicrob Chemother; 2009 May; 63 Suppl 1():i14-5. PubMed ID: 19372173
[TBL] [Abstract][Full Text] [Related]
6. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.
Cordonnier C; Pautas C; Maury S; Vekhoff A; Farhat H; Suarez F; Dhédin N; Isnard F; Ades L; Kuhnowski F; Foulet F; Kuentz M; Maison P; Bretagne S; Schwarzinger M
Clin Infect Dis; 2009 Apr; 48(8):1042-51. PubMed ID: 19281327
[TBL] [Abstract][Full Text] [Related]
7. Antibiotic use in neonatal sepsis.
Yurdakök M
Turk J Pediatr; 1998; 40(1):17-33. PubMed ID: 9722468
[TBL] [Abstract][Full Text] [Related]
8. Prophylaxis and treatment of bacterial infections: do we need new strategies?
Micozzi A; Bucaneve G
Rev Clin Exp Hematol; 2005 Dec; 9(2):E4. PubMed ID: 16864118
[TBL] [Abstract][Full Text] [Related]
9. [Empiric antibiotic therapy for treatment of infection in patients with severe neutropenia].
Bajko G; Kubiak A; Hansz J
Acta Haematol Pol; 1995; 26(1):15-26. PubMed ID: 7747558
[TBL] [Abstract][Full Text] [Related]
10. Febrile neutropenia in haematological malignancies.
Sharma A; Lokeshwar N
J Postgrad Med; 2005; 51 Suppl 1():S42-8. PubMed ID: 16519255
[TBL] [Abstract][Full Text] [Related]
11. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia.
Glasmacher A; Cornely O; Ullmann AJ; Wedding U; Bodenstein H; Wandt H; Boewer C; Pasold R; Wolf HH; Hänel M; Dölken G; Junghanss C; Andreesen R; Bertz H;
J Antimicrob Chemother; 2006 Feb; 57(2):317-25. PubMed ID: 16339606
[TBL] [Abstract][Full Text] [Related]
12. [Management of febrile neutropenic patients].
Takata T; Tamura K
Gan To Kagaku Ryoho; 2006 Jan; 33(1):13-8. PubMed ID: 16410691
[TBL] [Abstract][Full Text] [Related]
13. Initial empirical antimicrobial therapy: duration and subsequent modifications.
Tamura K
Clin Infect Dis; 2004 Jul; 39 Suppl 1():S59-64. PubMed ID: 15250024
[TBL] [Abstract][Full Text] [Related]
14. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Summary and comments.
Sinkó J; Kullberg BJ; Edwards JE; Anaissie E
J Antimicrob Chemother; 2009 May; 63 Suppl 1():i41-3. PubMed ID: 19372182
[No Abstract] [Full Text] [Related]
15. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group.
Kern W; Behre G; Rudolf T; Kerkhoff A; Grote-Metke A; Eimermacher H; Kubica U; Wörmann B; Büchner T; Hiddemann W
Cancer; 1998 Jul; 83(2):291-301. PubMed ID: 9669812
[TBL] [Abstract][Full Text] [Related]
16. Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients.
Bennett JE; Powers J; Walsh T; Viscoli C; de Pauw B; Dismukes W; Galgiani J; Glauser M; Herbrecht R; Kauffman C; Lee J; Pappas P; Rex J; Verweij P
Clin Infect Dis; 2003 Apr; 36(Suppl 3):S117-22. PubMed ID: 12679895
[TBL] [Abstract][Full Text] [Related]
17. Antifungal treatment strategies in high risk patients.
Rüping MJ; Vehreschild JJ; Cornely OA
Mycoses; 2008 Sep; 51 Suppl 2():46-51. PubMed ID: 18721331
[TBL] [Abstract][Full Text] [Related]
18. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Where do we go from here?
Pizzo PA
J Antimicrob Chemother; 2009 May; 63 Suppl 1():i16-7. PubMed ID: 19372174
[TBL] [Abstract][Full Text] [Related]
19. Wait and see or rush and switch? New questions for the management of patients with febrile neutropenia receiving antifungal prophylaxis.
Karthaus M; Hentrich M
Mycoses; 2011 Jan; 54 Suppl 1():1-6. PubMed ID: 21126265
[TBL] [Abstract][Full Text] [Related]
20. [Clinical study on fluoroquinolone prophylaxis in neutropenia patients with acute leukemia].
Qin TJ; Mi YC; Feng SZ; Li DP; Wei JL; Yang DL; Han MZ; Wang JX; Bian SG
Zhonghua Yi Xue Za Zhi; 2007 May; 87(20):1389-93. PubMed ID: 17785058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
